(Reuters) – Action Sartorius Stedim Biotech is about to record its strongest daily fall on Tuesday in one year, after having kept its annual prospects despite solid quarterly results.
The supplier of French pharmaceutical equipment reported an increase of 19.3% of its profit before interest, taxes, depreciation and depreciation (EBITDA) running in the first half, at 462 million euros, due to “volumes and effects of the product range, as well as economies of scale”.
At the Paris Stock Exchange, the title Sartorius Stedim Biotech ceded 8.77% to 173.75 euros at 8:18 GMT.
The French subsidiary of the German Sartorius AG confirmed Tuesday its forecast of the margin of Ebitda running from 30 to 31% as announced in April, against 28% the previous year, and organic growth in turnover of approximately 7% for the 2025 financial year, invoking “the expected prosecution of the positive development of the market”.
According to JP Morgan analysts, “the median point of turnover and EBITDA forecasts implies a level of approximately 3% compared to the Vara consensus, which again means that the extent of the lever lever effect was not modeled”.
His parent company also fell back on Tuesday on the Frankfurt Stock Exchange, 4.6%, despite an increase in turnover and profit in the first half.
“Given that we do not expect the consensus to evolve after this updating, we expect the underperforming actions today, although a part of this potential weakness has already been reflected during last week,” add JP Morgan’s analysts in a note.
(Written by Elena Smirnova and Coralie Lamarque, edited by Diana Mandia and Kate Entringer)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
